Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective

Ítems similars

• P731: SURVIVAL IN LOWER-RISK MDS PATIENTS FROM EUMDS REGISTRY BY TWO TRANSPLANT SELECTION CRITERIA - IMPLICATIONS FOR TRANSPLANT DECISION
  per: Aleksandar Savic, et al.
  Publicat: (2023-08-01)
• Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective
  per: Theo de Witte, et al.
  Publicat: (2020-09-01)
• Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry
  per: Marlijn Hoeks, et al.
  Publicat: (2020-03-01)
• S168: ERYTHROPOIETIN STIMULATION AGENTS SIGNIFICANTLY IMPROVES OUTCOME IN LOWER RISK MDS.
  per: H. Garelius, et al.
  Publicat: (2022-06-01)
• Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes
  per: Louise de Swart, et al.
  Publicat: (2020-03-01)